Spots Global Cancer Trial Database for Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Official Title: Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial

Study ID: NCT00238290

Conditions

Breast Cancer

Interventions

Trastuzumab + Letrozole

Study Description

Brief Summary: RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving trastuzumab together with letrozole after disease progression may be an effective treatment for breast cancer. PURPOSE: This phase II trial is studying how well giving trastuzumab together with letrozole works in treating postmenopausal women with progressive advanced breast cancer.

Detailed Description: OBJECTIVES: Primary * Determine the efficacy of trastuzumab (Herceptin®) monotherapy followed by trastuzumab and letrozole in women with progressive advanced breast cancer that is resistant to prior treatment with a nonsteroidal aromatase inhibitor. Secondary * Determine the safety profile of this regimen in these patients. * Correlate HER-2-extracellular domain (ECD) levels with response to treatment in these patients. * Determine the efficacy of this regimen in these patients. * Correlate response and time to tumor progression with changes in serum HER-2-ECD levels in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 12 weeks until disease progression and then at 6 months. PROJECTED ACCRUAL: A total of 30-40 patients will be accrued for this study.